Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin

Thrombosis Research

Volumn 118, Issue 3, 2006, Pages 361-369

  Keating, Friederike K ^a   Dauerman, Harold L ^a   Whitaker, Deborah A ^a   Sobel, Burton E ^a   Schneider, David J ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Anticoagulants; Leukocytes; Percutaneous revascularization; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; MYELOPEROXIDASE; PADGEM PROTEIN; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD ANALYSIS; CELL AGGREGATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE AGGREGATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS;

ANTICOAGULANTS; CELLS, CULTURED; DRUG COMBINATIONS; FEMALE; HEPARIN; HIRUDINS; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 33745989916     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.07.020     Document Type: Article

References (42)

1. Schneider D.J., Tracy P.B., Mann K.G., and Sobel B.E. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 96 (1997) 2877-2883
2. Aggarwal A., Sobel B.E., and Schneider D.J. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13 (2002) 161-165
3. Klein B., Faridi A., von Tempelhoff G.F., Heilmann L., Mittermayer C., and Rath W. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 108 (2002) 291-296
4. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 352 (1998) 87-92
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
6. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
7. ESPRIT Investigators. Enhanced suppression of the Platelet IIb/IIIa receptor with integrilin therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356 (2000) 2037-2044
8. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
9. Scholz T., Zhao L., Temmler U., Bath P., Heptinstall S., and Losche W. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets 13 (2002) 401-406
10. Dalby M., Montalescot G., Bal dit Sollier C., Vicaut E., Soulat T., Collet J.P., et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 43 (2004) 162-168
11. Kabbani S.S., Watkins M.W., Holoch P.A., Terrien E.F., Sobel B.E., and Schneider D.J. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. J Thromb Thrombolysis 12 (2001) 171-176
12. Aggarwal A., Schneider D.J., Terrien E.F., Sobel B.E., and Dauerman H.L. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 93 (2004) 6-9
13. Holmes M.B., Sobel B.E., Howard D.B., and Schneider D.J. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 95 (1999) 75-82
14. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Holoch P.A., Sobel B.E., et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 104 (2001) 181-186
15. Barnard M.R., Krueger L.A., Frelinger A.L., Furman M.L., and Michelson A.D. Whole blood analysis of leukocyte-platelet aggregates. Cur Protoc Cytometry (2003) 6.15.1-6.15.8
16. Furman M.I., Kereiakes D.J., Krueger L.A., Mueller M.N., Pieper K., Broderick T.M., et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 142 (2001) 790-798
17. Schneider D.J., Herrmann H.C., Lakkis N., Aguirre F., Lo M.W., Yin K.C., et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 91 (2003) 334-336
18. Rubens F.D., Weitz J.I., Brash J.L., and Kinlough-Rathbone R.L. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene. Thromb Haemost 69 (1993) 130-134
19. Weitz J.I., and Crowther M. Direct thrombin inhibitors. Thromb Res 106 (2002) V275-V284
20. + signaling. Eur J Biochem 249 (1997) 547-555
21. Day J.R., Malik I.S., Weerasinghe A., Poullis M., Nadra I., Haskard D.O., et al. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart 90 (2004) 794-799
22. Kozek-Langenecker S.A., Mohammad S.F., Masaki T., Kamerath C., and Cheung A.K. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 90 (2000) 808-812
23. Knight C.J., Panesar M., Wilson D.J., Patrineli A., Chronos N., Wright C., et al. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 19 (1998) 1239-1248
24. Aggarwal A., Whitaker D.A., Rimmer J.M., Solomon R.J., Gennari F.J., Sobel B.E., et al. Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant 19 (2004) 1559-1563
25. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
26. Peter K., Schwarz M., Ylanne J., Kohler B., Moser M., Nordt T., et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 92 (1998) 3240-3249
27. Caron A., Theoret J.F., Mousa S.A., and Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovasc Pharmacol 40 (2002) 296-306
28. Massberg S., Mueller I., Besta F., Thomas P., and Gawaz M. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. Am Heart J 146 (2003) E19
29. Xiao Z., Theroux P., and Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost 81 (1999) 281-285
30. McEver R.P. Leukocyte interactions mediated by selectins. Thromb Haemost 65 (1991) 223-228
31. Palabrica T., Lobb R., Furie B.C., Aronovitz M., Benjamin C., Hsu Y.M., et al. Leukocyte accumulation promoting fibrin deposition is mediated by P-selectin on adherent platelets. Nature 359 (1992) 848-851
32. Tsuji T., Nagata K., Koike J., Todoroki N., and Irimura T. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 151 (1993) 3267-3273
33. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 (2003) 61-67
34. Schober A., Manka D., von Hundelshausen P., Huo Y., Hanrath P., Sarembock I.J., et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106 (2002) 1523-1529
35. Smyth S.S., Reis E.D., Vaananen H., Zhang W., and Coller B.S. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation 103 (2001) 2501-2507
36. Sugiyama S., Kugiyama K., Aikawa M., Nakamura S., Ogawa H., and Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 24 (2004) 1309-1314
37. Furman M.I., Benoit S.E., Barnard M.R., Valeri C.R., Borbone M.L., Becker R.C., et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 31 (1998) 352-358
38. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., and Furman M.I. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38 (2001) 1002-1006
39. Faraday N., Braunstein J.B., Heldman A.W., Bolton E.D., Chiles K.A., Gerstenblith G., et al. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets 15 (2004) 9-14
40. Sarma J., Laan C.A., Alam S., Jha A., Fox K.A., and Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 105 (2002) 2166-2171
41. Brennan M.L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
42. Limbruno U., Micheli A., De Carlo M., Amoroso G., Rossini R., Palagi C., et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 08 (2003) 171-176